(RDY) Dr. Reddy’s Laboratories - Overview
Exchange: NYSE •
Country: India •
Currency: USD •
Type: Common Stock •
ISIN: US2561352038
Stock:
Total Rating 55
Risk 86
Buy Signal -0.36
| Risk 5d forecast | |
|---|---|
| Volatility | 22.8% |
| Relative Tail Risk | -2.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.42 |
| Alpha | 0.96 |
| Character TTM | |
|---|---|
| Beta | 0.467 |
| Beta Downside | 0.579 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.61% |
| CAGR/Max DD | 0.48 |
EPS (Earnings per Share)
Revenue
Description: RDY Dr. Reddy’s Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 56.59b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 4.03 > 1.0 |
| NWC/Revenue: 40.26% < 20% (prev 38.89%; Δ 1.37% < -1%) |
| CFO/TA 0.11 > 3% & CFO 63.11b > Net Income 56.59b |
| Net Debt (49.08b) to EBITDA (93.77b): 0.52 < 3 |
| Current Ratio: 1.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (833.2m) vs 12m ago -0.13% < -2% |
| Gross Margin: 55.18% > 18% (prev 0.59%; Δ 5459 % > 0.5%) |
| Asset Turnover: 66.25% > 50% (prev 64.71%; Δ 1.54% > 0%) |
| Interest Coverage Ratio: 22.23 > 6 (EBITDA TTM 93.77b / Interest Expense TTM 3.34b) |
Altman Z'' 6.60
| A: 0.25 (Total Current Assets 297.55b - Total Current Liabilities 158.31b) / Total Assets 562.90b |
| B: 0.62 (Retained Earnings 349.78b / Total Assets 562.90b) |
| C: 0.14 (EBIT TTM 74.35b / Avg Total Assets 521.98b) |
| D: 1.89 (Book Value of Equity 354.60b / Total Liabilities 187.14b) |
| Altman-Z'' Score: 6.60 = AAA |
Beneish M -2.92
| DSRI: 1.00 (Receivables 124.27b/111.49b, Revenue 345.83b/311.31b) |
| GMI: 1.07 (GM 55.18% / 59.31%) |
| AQI: 0.95 (AQ_t 0.27 / AQ_t-1 0.28) |
| SGI: 1.11 (Revenue 345.83b / 311.31b) |
| TATA: -0.01 (NI 56.59b - CFO 63.11b) / TA 562.90b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of RDY shares?
As of March 01, 2026, the stock is trading at USD 14.38 with a total of 946,372 shares traded.
Over the past week, the price has changed by -0.76%, over one month by +4.89%, over three months by +2.35% and over the past year by +11.74%.
Over the past week, the price has changed by -0.76%, over one month by +4.89%, over three months by +2.35% and over the past year by +11.74%.
Is RDY a buy, sell or hold?
Dr. Reddy’s Laboratories has received a consensus analysts rating of 3.50.
Therefor, it is recommend to hold RDY.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the RDY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.4 | 0.3% |
| Analysts Target Price | 14.4 | 0.3% |
RDY Fundamental Data Overview February 28, 2026
Market Cap INR = 1112.34b (12.24b USD * 90.869 USD.INR)
P/E Trailing = 19.44
P/E Forward = 25.1889
P/S = 0.0354
P/B = 2.9639
P/EG = 3.8131
Revenue TTM = 345.83b INR
EBIT TTM = 74.35b INR
EBITDA TTM = 93.77b INR
Long Term Debt = 3.80b INR (from longTermDebt, last fiscal year)
Short Term Debt = 56.12b INR (from shortTermDebt, last quarter)
Debt = 67.73b INR (from shortLongTermDebtTotal, last quarter)
Net Debt = 49.08b INR (from netDebt column, last quarter)
Enterprise Value = 1097.49b INR (1112.34b + Debt 67.73b - CCE 82.59b)
Interest Coverage Ratio = 22.23 (Ebit TTM 74.35b / Interest Expense TTM 3.34b)
EV/FCF = 45.24x (Enterprise Value 1097.49b / FCF TTM 24.26b)
FCF Yield = 2.21% (FCF TTM 24.26b / Enterprise Value 1097.49b)
FCF Margin = 7.01% (FCF TTM 24.26b / Revenue TTM 345.83b)
Net Margin = 16.36% (Net Income TTM 56.59b / Revenue TTM 345.83b)
Gross Margin = 55.18% ((Revenue TTM 345.83b - Cost of Revenue TTM 155.00b) / Revenue TTM)
Gross Margin QoQ = 53.63% (prev 54.67%)
Tobins Q-Ratio = 1.95 (Enterprise Value 1097.49b / Total Assets 562.90b)
Interest Expense / Debt = 1.41% (Interest Expense 951.8m / Debt 67.73b)
Taxrate = 22.90% (3.53b / 15.43b)
NOPAT = 57.33b (EBIT 74.35b * (1 - 22.90%))
Current Ratio = 1.88 (Total Current Assets 297.55b / Total Current Liabilities 158.31b)
Debt / Equity = 0.18 (Debt 67.73b / totalStockholderEquity, last quarter 372.37b)
Debt / EBITDA = 0.52 (Net Debt 49.08b / EBITDA 93.77b)
Debt / FCF = 2.02 (Net Debt 49.08b / FCF TTM 24.26b)
Total Stockholder Equity = 353.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.84% (Net Income 56.59b / Total Assets 562.90b)
RoE = 16.00% (Net Income TTM 56.59b / Total Stockholder Equity 353.58b)
RoCE = 20.81% (EBIT 74.35b / Capital Employed (Equity 353.58b + L.T.Debt 3.80b))
RoIC = 14.36% (NOPAT 57.33b / Invested Capital 399.34b)
WACC = 7.26% (E(1112.34b)/V(1180.08b) * Re(7.64%) + D(67.73b)/V(1180.08b) * Rd(1.41%) * (1-Tc(0.23)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 123.5%
[DCF] Terminal Value 80.49% ; FCFF base≈15.10b ; Y1≈14.67b ; Y5≈14.66b
[DCF] Fair Price = 304.4 (EV 302.48b - Net Debt 49.08b = Equity 253.41b / Shares 832.6m; r=7.26% [WACC]; 5y FCF grow -3.95% → 2.90% )
EPS Correlation: 26.47 | EPS CAGR: 25.22% | SUE: 0.00 | # QB: 0
Revenue Correlation: 60.37 | Revenue CAGR: 259.1% | SUE: 0.03 | # QB: 0
EPS next Year (2027-03-31): EPS=51.82 | Chg7d=-4.800 | Chg30d=-4.800 | Revisions Net=-1 | Growth EPS=-8.0% | Growth Revenue=+3.6%
P/E Trailing = 19.44
P/E Forward = 25.1889
P/S = 0.0354
P/B = 2.9639
P/EG = 3.8131
Revenue TTM = 345.83b INR
EBIT TTM = 74.35b INR
EBITDA TTM = 93.77b INR
Long Term Debt = 3.80b INR (from longTermDebt, last fiscal year)
Short Term Debt = 56.12b INR (from shortTermDebt, last quarter)
Debt = 67.73b INR (from shortLongTermDebtTotal, last quarter)
Net Debt = 49.08b INR (from netDebt column, last quarter)
Enterprise Value = 1097.49b INR (1112.34b + Debt 67.73b - CCE 82.59b)
Interest Coverage Ratio = 22.23 (Ebit TTM 74.35b / Interest Expense TTM 3.34b)
EV/FCF = 45.24x (Enterprise Value 1097.49b / FCF TTM 24.26b)
FCF Yield = 2.21% (FCF TTM 24.26b / Enterprise Value 1097.49b)
FCF Margin = 7.01% (FCF TTM 24.26b / Revenue TTM 345.83b)
Net Margin = 16.36% (Net Income TTM 56.59b / Revenue TTM 345.83b)
Gross Margin = 55.18% ((Revenue TTM 345.83b - Cost of Revenue TTM 155.00b) / Revenue TTM)
Gross Margin QoQ = 53.63% (prev 54.67%)
Tobins Q-Ratio = 1.95 (Enterprise Value 1097.49b / Total Assets 562.90b)
Interest Expense / Debt = 1.41% (Interest Expense 951.8m / Debt 67.73b)
Taxrate = 22.90% (3.53b / 15.43b)
NOPAT = 57.33b (EBIT 74.35b * (1 - 22.90%))
Current Ratio = 1.88 (Total Current Assets 297.55b / Total Current Liabilities 158.31b)
Debt / Equity = 0.18 (Debt 67.73b / totalStockholderEquity, last quarter 372.37b)
Debt / EBITDA = 0.52 (Net Debt 49.08b / EBITDA 93.77b)
Debt / FCF = 2.02 (Net Debt 49.08b / FCF TTM 24.26b)
Total Stockholder Equity = 353.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.84% (Net Income 56.59b / Total Assets 562.90b)
RoE = 16.00% (Net Income TTM 56.59b / Total Stockholder Equity 353.58b)
RoCE = 20.81% (EBIT 74.35b / Capital Employed (Equity 353.58b + L.T.Debt 3.80b))
RoIC = 14.36% (NOPAT 57.33b / Invested Capital 399.34b)
WACC = 7.26% (E(1112.34b)/V(1180.08b) * Re(7.64%) + D(67.73b)/V(1180.08b) * Rd(1.41%) * (1-Tc(0.23)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 123.5%
[DCF] Terminal Value 80.49% ; FCFF base≈15.10b ; Y1≈14.67b ; Y5≈14.66b
[DCF] Fair Price = 304.4 (EV 302.48b - Net Debt 49.08b = Equity 253.41b / Shares 832.6m; r=7.26% [WACC]; 5y FCF grow -3.95% → 2.90% )
EPS Correlation: 26.47 | EPS CAGR: 25.22% | SUE: 0.00 | # QB: 0
Revenue Correlation: 60.37 | Revenue CAGR: 259.1% | SUE: 0.03 | # QB: 0
EPS next Year (2027-03-31): EPS=51.82 | Chg7d=-4.800 | Chg30d=-4.800 | Revisions Net=-1 | Growth EPS=-8.0% | Growth Revenue=+3.6%